Pharmaceuticals, Biotechnology & Life Sciences

Oncolytics CEO’s fresh ADS purchase signals confidence amid falling stock, hinting at future growth from REOLYSIN and AI‑powered oncology deals.

Repligen CFO’s disciplined 530‑share sale shows insider liquidity management, not market risk, reinforcing the company’s growth outlook and bioprocessing leadership.

Inside Kodiak Sciences’ surge: insider buys, Phase III success of KOD‑001, and FDA/EMA milestones suggest a promising valuation climb for the rare‑disease biotech.

Insiders buy Exicure shares at $4.50, signaling confidence in its CAR‑T pipeline and hinting at a strategic shift that could lift stock value.

Insightful look at United Therapeutics’ CEO buying & selling – see how Martine Rothblatt’s trades signal confidence and liquidity.

CareDx CEO’s insider buying at $8‑$9 shares signals confidence in the company’s expanded Medicare coverage and growth prospects – a bullish hint for investors.

Insider selling at Bausch Health: President Lenar Aimee J. sold 23,395 shares at $4.89 amid a 21.9% yearly decline, raising questions about the company’s near‑term outlook.

Angel Pharma’s 2026 merger with Catalyst: insider sales, regulatory compliance, and strategic synergies that boost rare‑disease pipeline speed and investor confidence.

Palatin Technologies insider sales reveal liquidity moves amid volatile biotech markets—understand how tax‑withholding trades impact stock, sentiment, and future pipeline prospects.

Ardelyx CEO Michael Raab’s latest 10b5‑1 trades show disciplined buying at $0.99 and selling near $5, confirming long‑term confidence amid volatility.